RecruitingNCT05167487

Pathological Response After Neoadjuvant Treatment on NSCLC

Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient Outcomes

Sponsor

Fundación GECP

Enrollment

150 participants

Start Date

Dec 13, 2021

Study Type

OBSERVATIONAL

Conditions

Stage IIIA Non-small Cell Lung Cancer

Summary

This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is analyzing the outcomes of patients with stage IIIA non-small cell lung cancer (NSCLC) who received chemotherapy before surgery (neoadjuvant treatment) between 2010 and 2017. Researchers want to understand which patients respond best to this approach. **You may be eligible if...** - You were treated at a participating center between 2010 and 2017 - You had stage IIIA NSCLC with confirmed lymph node involvement (N2 disease) - You received platinum-based chemotherapy before surgery (neoadjuvant treatment) - You had a PET/CT scan at the time of diagnosis - You are 18 years of age or older **You may NOT be eligible if...** - You received combined chemotherapy and radiation before surgery - You did not have surgery after your neoadjuvant treatment - You were diagnosed after June 2017 Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCisplatin

Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.

DRUGCarboplatin

Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.

Locations(17)

Hospital Universitario De A Coruna

A Coruña, A Coruña, Spain

Hospital General Universitario de Alicante

Alicante, Alicante, Spain

ICO Badalona, Hospital Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital Vall d'Hebron

Barcelona, Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain

ICO Hospitalet

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario Insular de Gran canaria

Las Palmas de Gran Canaria, Gran Canaria, Spain

Hospital Dr. Negrín

Las Palmas de Gran Canaria, Las Palmas, Spain

Hospital Clínico San Carlos

Madrid, Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Madrid, Spain

Hospital 12 De Octubre

Madrid, Madrid, Spain

Hospital Universitario la Paz

Madrid, Madrid, Spain

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain

Hospital Universitario Regional de Málaga

Málaga, Málaga, Spain

Complejo Hospitalario Universitario de Vigo

Vigo, Pontevedra, Spain

Hospital Universitario La Fe

Valencia, Valencia, Spain

Hospital Universitario Cruces

Barakaldo, Vizcaya, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05167487